Ablation
ProcedurePulsed field ablation, MRI and TEE examinations (LA strain)
NCT Number: NCT06478342
Introduction: Pulsed field ablation (PFA) has emerged in routine clinical practice as a new promising technology in catheter-based treatment of atrial fibrillation (AF). The ease of PFA technology enables more extensive ablation in shorter time. On one hand, extensive ablation is advocated to decrease the AF recurrence in persistent patients, on the other hand it is an important predictor of developing left atrial stiff syndrome with a reported incidence rate of 3.7 - 8.2 % in persistent patients during the era of radiofrequency ablation.
Goals of the study: The main hypothesis is that the LA function (strain) will tend to decline after extensive PFA. It will be assessed using transthoracic echocardiography (TTE) and magnetic resonance (MRI).
Secondary endpoint analysis will include the evaluation of the distribution of late gadolinium enhancement (LGE) after ablation compared to baseline scans, evaluation of heart failure biomarkers after ablation, and description of the rate of AF recurrence.
Methods: This project is a prospective, nonrandomised, two-centre (University Hospital Kralovske Vinohrady and University Hospital Motol) observational study including 50 non-paroxysmal AF patients with indication for catheter ablation. Before the ablation, all patients will undergo LGE MRI and TTE (after cardioversion if AF present). The ablation procedure will be performed using pulsed field technology and will include pulmonary vein isolation, posterior wall ablation and mitral isthmus ablation. Patients will be followed for 6 months. 3 months after the ablation, LGE MRI will be performed. TTE examinations will be carried out on the day after the ablation, at 3 and at 6 months. Heart failure biomarkers (N-terminal proatrial natriuretic peptide, fibroblast growth factor 23, and galectin 3) levels will be analysed at baseline, and 3 and 6 months after the procedure. ECG Holter monitoring will be performed at 3- and 6-months visits.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pulsed field ablation, MRI and TEE examinations (LA strain)
Time frame: Baseline MRI to 3 months after procedure
LA strain (baseline vs. 3 months)
Time frame: Procedure to 3 months
LA strain (baseline vs. 3 months)
Time frame: Baseline MRI to 3 months after procedure
LGE evaluation (baseline vs. 3 months MRI)
Time frame: baseline vs. 3 m values
laboratory analysis
Time frame: Procedure to 6 months visit
defined as an absence of AF/atrial tachycardia lasting > 30 s during follow-up including Holter monitoring
Time frame: baseline TTE to 6 months control
comparison of strain values obtained at all 4 time points
Contact information is provided by the study sponsor or research team.
Charles University, Czech Republic
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07511166
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT07625215
Arrhythmias, Cardiac, Atrial Fibrillation
San Francisco, California, United States
View Trial DetailsNCT07560644
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT07724301
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial Details